 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > AEterna Laboratories Inc.
 |
AEterna Laboratories Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Aeterna Laboratories makes profit on one-off gain Jul 18 2001 07:56 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
AEterna Laboratories knows seriously ill patients won't wait an eternity for a new drug, so the firm is working to take lead drug candidate Neovastat through trials and to approval as quickly as possible. Derived from shark cartilage, the compound inhibits angiogenesis, the formation of new blood vessels crucial to the spread of such diseases as cancer. AEterna is testing Neovastat to treat kidney, lung, and a type of blood cancer, as well as psoriasis and age-related macular degeneration (which leads to blindness). Its 64%-owned Atrium Biotechnologies unit, which funds AEterna's R&D, makes ingredients and additives for the cosmetic and nutritional markets; Estée Lauder accounts for about 40% of its sales.
COMPETITION |
 |
EntreMed, Inc. (ENMD)
ImClone Systems Incorporated (IMCL)
SUGEN, Inc. (dossier)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 5.60
1-Yr. Sales Growth: 30.2%
Employees: 150
Revenue per employee: $37,333.33
KEY PEOPLE |
 |
Éric Dupont
CEO
Dennis Turpin
CFO
CONTACT INFO |
 |
1405 Parc-Technologique Blvd.
Quebec City Quebec G1P 4P5, Canada
Phone: 1-418-652-8525
Fax: 1-418-652-0881
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |